Garth Kinberger

Garth brings to Atalanta nearly 20 years of oligonucleotide therapeutics research and development experience. His most recent experience was as Executive Director of Chemistry and Pharmaceutical Development, at Regulus Therapeutics, where he assumed roles of increasing responsibility during his over 5-year tenure. Prior to Regulus, Garth was at Ionis Pharmaceuticals for 13 years where he conducted research in PNA, microRNA, siRNA, ss-siRNA, splicing, and gapmer based therapeutics. Garth received his B.S. in Chemistry from Sonoma State University as well as his M.S. and Ph.D. in Chemistry and Biochemistry from the University of California, San Diego.